

# Quiz Page — Treatment of Rheumatoid Arthritis

**1. Which of the following statements best describes the mode of action of abatacept?**

- a. Abatacept acts by selectively modulating the interaction between T cells and antigen presenting cells
- b. Abatacept acts by depleting T cells
- c. Abatacept acts by depleting antigen presenting cells
- d. Abatacept acts by upregulating CTLA-4 expression

**2. Which one of the following statements is not true?**

- a. Abatacept is indicated for reducing the signs and symptoms of RA
- b. Abatacept is indicated for slowing the progression of structural damage in RA
- c. Abatacept may be administered concomitantly with TNF antagonists
- d. Abatacept is not recommended for use concomitantly with anakinra

**3. Abatacept has been shown to provide benefit to patients with an inadequate response to which other RA therapy/therapies?**

- a. MTX only
- b. TNF antagonists only
- c. Neither A nor B
- d. Both A and B

**4. After the first infusion, abatacept is administered at 2 and 4 weeks. What is the recommended dosing regimen for abatacept thereafter?**

- a. 2 mg/kg (according to weight range) every 2 weeks
- b. 2 mg/kg (according to weight range) every 4 weeks
- c. 10 mg/kg (according to weight range) every 2 weeks
- d. 10 mg/kg (according to weight range) every 4 weeks

**5. In patients with RA, the mean (range) half-life of abatacept is:**

- a. 13.1 (8–25) days
- b. 15.7 (9–31) days
- c. 11.5 (7–23) days
- d. 9.9 (5–20) days

**6. In patients with rheumatoid arthritis, abatacept is cleared from the body at which of the following rates?**

- a. 0.01 mL/hour/kg
- b. 0.5 mL/hour/kg
- c. 0.22 mL/hour/kg
- d. 0.1 mL/hour/kg

**7. Why is abatacept not recommended for addition to a background of biologic therapy?**

- a. Lack of efficacy
- b. Risk of severe infusion reactions
- c. Increased rate of infection
- d. Increased rate of malignancy

**8. Abatacept may blunt the effectiveness of some immunizations. Therefore live vaccines should not be given concurrently with abatacept, and for \_\_\_\_ after discontinuation of the drug.**

- a. 6 months
- b. 12 months
- c. 3 months
- d. 1 month

**9. Which of the following statements best describes the mode of action of rituximab?**

- a. Rituximab acts by depleting circulating and tissue-based B cells
- b. Rituximab acts by depleting T cells
- c. Rituximab acts by binding to CD20 on B cells and preventing their interaction with T cells
- d. Rituximab acts by upregulating CD20 on B cells

**10. Transient hypotension may occur during rituximab infusion, so consideration should be given to withholding antihypertensive medications for how long prior to rituximab infusion?**

- a. 2 hours
- b. 12 hours
- c. 24 hours
- d. 36 hours

**11. Rituximab is indicated in combination with MTX to reduce signs and symptoms in adult patients with moderately to severely active RA who have had an inadequate response to**

- a. MTX only
- b. TNF antagonists only
- c. Neither A nor B
- d. Both A and B

**12. After the first infusion of rituximab, a second infusion is administered at 2 weeks. What is the recommended dose of this second infusion?**

- a. 100 mg IV
- b. 1000 mg IV
- c. 500 mg IV
- d. 250 mg IV

**13. The mean terminal elimination half-life of rituximab after the second dose is:**

- a. 12 days
- b. 17 days
- c. 19 days
- d. 23 days

**14. The most common adverse events with rituximab were infusion associated. What percentage of patients treated with rituximab experienced an adverse event during or within 24 hours following their first infusion?**

- a. 23%
- b. 50%
- c. 32%
- d. 5%

**15. In order to reduce the frequency and severity of infusion reactions associated with rituximab treatment, it is recommended that the following premedication should be administered:**

- a. Acetaminophen
- b. An antihistamine
- c. Neither A nor B
- d. Both A and B

**NOTE: THIS DOCUMENT IS NOT VALID FOR CREDIT. DO NOT MAIL THIS DOCUMENT TO ELF PUBLICATIONS. YOU SHOULD COMPLETE THE EXAM ONLINE.**